Fingolimod reduces annualised relapse rates and the risk of 3-month confirmed disability progression versus placebo: subgroup analysis from the 2-year FREEDOMS study in relapsing multiple sclerosis: O209


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles